Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Leukemia, Lymphoid

ClinicalTrials.gov lists 4,331 trials for Leukemia, Lymphoid or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 250.

MeSH D007945 Neoplasms Neoplasm C04 C15 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,084 Phase 1/2 Phase 1/2 497 Phase 2 Phase 2 1,228 Phase 2/3 Phase 2/3 56 Phase 3 Phase 3 308 Phase 4 Phase 4 81 Not applicable Not applicable 436 Observational Observational 620 Phase 1 Phase 1 1,084 Phase 1/2 Phase 1/2 497 Phase 2 Phase 2 1,228 Phase 2/3 Phase 2/3 56 Phase 3 Phase 3 308 Phase 4 Phase 4 81 Not applicable Not applicable 436 Observational Observational 620

Trials per phase (log scale)

2 more sections with rows

89 of the 4,331 trials are tagged with Leukemia, Lymphoid itself; the rest are tagged with a narrower condition beneath it.

Get the Leukemia, Lymphoid report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Leukemia, Lymphoid trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 12 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 199

1990: 5 trials (Not applicable 1, Phase 2/3 1, Phase 2 3) 1991: 4 trials (Observational 1, Phase 2 3) 1992: 8 trials (Observational 2, Phase 3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 1993: 9 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 2, Phase 2 4) 1994: 9 trials (Phase 3 2, Phase 2 4, Phase 1 3) 1995: 22 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 7, Phase 1/2 3, Phase 1 5) 1996: 34 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 6, Phase 2 14, Phase 1/2 2, Phase 1 8) 1997: 46 trials (Observational 1, Not applicable 3, Phase 4 1, Phase 3 9, Phase 2/3 1, Phase 2 15, Phase 1/2 3, Phase 1 13) 1998: 67 trials (Observational 3, Not applicable 1, Phase 4 1, Phase 3 8, Phase 2/3 1, Phase 2 27, Phase 1/2 5, Phase 1 21) 1999: 95 trials (Observational 4, Not applicable 6, Phase 4 1, Phase 3 11, Phase 2/3 1, Phase 2 30, Phase 1/2 9, Phase 1 33) 2000: 92 trials (Observational 4, Not applicable 9, Phase 4 3, Phase 3 10, Phase 2/3 2, Phase 2 38, Phase 1/2 6, Phase 1 20) 2001: 78 trials (Observational 5, Not applicable 9, Phase 4 1, Phase 3 7, Phase 2/3 2, Phase 2 25, Phase 1/2 10, Phase 1 19) 2002: 93 trials (Observational 7, Not applicable 7, Phase 4 1, Phase 3 8, Phase 2/3 1, Phase 2 35, Phase 1/2 9, Phase 1 25) 2003: 95 trials (Observational 9, Not applicable 10, Phase 4 6, Phase 3 10, Phase 2/3 1, Phase 2 30, Phase 1/2 14, Phase 1 15) 2004: 119 trials (Observational 11, Not applicable 8, Phase 4 2, Phase 3 8, Phase 2/3 1, Phase 2 44, Phase 1/2 9, Phase 1 36) 2005: 132 trials (Observational 14, Not applicable 9, Phase 4 3, Phase 3 5, Phase 2/3 1, Phase 2 48, Phase 1/2 22, Phase 1 30) 2006: 130 trials (Observational 9, Not applicable 8, Phase 4 1, Phase 3 8, Phase 2/3 1, Phase 2 43, Phase 1/2 19, Phase 1 41) 2007: 145 trials (Other 1, Observational 12, Not applicable 12, Phase 4 2, Phase 3 14, Phase 2/3 1, Phase 2 42, Phase 1/2 15, Phase 1 46) 2008: 157 trials (Observational 22, Not applicable 12, Phase 4 2, Phase 3 15, Phase 2/3 4, Phase 2 47, Phase 1/2 18, Phase 1 37) 2009: 154 trials (Other 1, Observational 21, Not applicable 8, Phase 4 2, Phase 3 17, Phase 2/3 3, Phase 2 46, Phase 1/2 18, Phase 1 38) 2010: 177 trials (Observational 26, Not applicable 10, Phase 4 4, Phase 3 5, Phase 2/3 1, Phase 2 61, Phase 1/2 19, Phase 1 51) 2011: 138 trials (Observational 21, Not applicable 6, Phase 4 2, Phase 3 6, Phase 2/3 1, Phase 2 52, Phase 1/2 14, Phase 1 36) 2012: 141 trials (Observational 14, Not applicable 4, Phase 4 1, Phase 3 16, Phase 2 50, Phase 1/2 18, Phase 1 38) 2013: 123 trials (Observational 14, Not applicable 7, Phase 4 5, Phase 3 15, Phase 2/3 2, Phase 2 29, Phase 1/2 17, Phase 1 34) 2014: 131 trials (Observational 13, Not applicable 8, Phase 3 15, Phase 2 34, Phase 1/2 19, Phase 1 42) 2015: 127 trials (Observational 11, Not applicable 9, Phase 4 3, Phase 3 8, Phase 2/3 1, Phase 2 44, Phase 1/2 19, Phase 1 32) 2016: 157 trials (Observational 22, Not applicable 10, Phase 4 3, Phase 3 10, Phase 2/3 6, Phase 2 37, Phase 1/2 26, Phase 1 43) 2017: 158 trials (Observational 27, Not applicable 10, Phase 4 3, Phase 3 8, Phase 2/3 1, Phase 2 50, Phase 1/2 27, Phase 1 32) 2018: 155 trials (Observational 36, Not applicable 16, Phase 4 3, Phase 3 7, Phase 2/3 2, Phase 2 36, Phase 1/2 20, Phase 1 35) 2019: 173 trials (Observational 27, Not applicable 24, Phase 4 3, Phase 3 13, Phase 2/3 5, Phase 2 40, Phase 1/2 17, Phase 1 44) 2020: 199 trials (Observational 49, Not applicable 20, Phase 4 1, Phase 3 6, Phase 2/3 2, Phase 2 39, Phase 1/2 18, Phase 1 64) 2021: 199 trials (Observational 41, Not applicable 32, Phase 4 6, Phase 3 12, Phase 2/3 2, Phase 2 37, Phase 1/2 22, Phase 1 47) 2022: 194 trials (Observational 43, Not applicable 36, Phase 4 2, Phase 3 9, Phase 2/3 1, Phase 2 31, Phase 1/2 22, Phase 1 50) 2023: 198 trials (Observational 54, Not applicable 36, Phase 4 5, Phase 3 8, Phase 2/3 1, Phase 2 30, Phase 1/2 20, Phase 1 44) 2024: 182 trials (Observational 38, Not applicable 32, Phase 4 4, Phase 3 5, Phase 2/3 1, Phase 2 48, Phase 1/2 20, Phase 1 34) 2025: 168 trials (Observational 27, Not applicable 28, Phase 4 4, Phase 3 9, Phase 2/3 6, Phase 2 45, Phase 1/2 20, Phase 1 29)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 163
2025 168
2024 182
2023 198
2022 194
2021 199
2020 199
2019 173
2018 155
2017 158

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 180 trials starting in 2026 and about 170 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 489 trials still running at the 2026-10-09 snapshot; registered median of 43 months across 2,727 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Leukemia, Lymphoid trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,084
Phase 1/2 497
Phase 2 1,228
Phase 2/3 56
Phase 3 308
Phase 4 81
Not applicable 436
Observational 620
Expanded access 20
Unknown 1

How many Leukemia, Lymphoid trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 119
Recruiting 560
Enrolling by invitation 21
Active, not recruiting 300
Available 6

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Leukemia, Lymphoid trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 250
Children's Oncology Group 77
Novartis Pharmaceuticals 41
AbbVie 38
Gilead Sciences 38

Which drugs are being tested for Leukemia, Lymphoid? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 575
RITUXIMAB 344

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SQ Fludarabine 432
HD- Methotrexate (MTX) 257
Cytarabine IT 252
Vincristina 213
Dexamethasone/Dexamethasone acetate 189

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Leukemia, Lymphoid trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 3,346 308
Pneumonia 2,542 238
Neutrophil count decreased 2,246 120
Platelet count decreased 1,793 123
Sepsis 1,550 314

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Leukemia, Lymphoid? (86)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016 Yes
Leukemia-free survival in myeloid leukemia, but not in lymphoid leukemia, is predicted by early CD4+ reconstitution following unrelated cord blood transplantation in children: a multicenter retrospective cohort analysis. Bone marrow transplantation 2016 Yes
Genomic Profile of Chronic Lymphocytic Leukemia in Korea Identified by Targeted Sequencing. PloS one 2016 Yes
Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PloS one 2014 Yes
Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. The Lancet. Infectious diseases 2013 Yes

Showing 5 of 86 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages